Provided by Tiger Trade Technology Pte. Ltd.

Capricor Therapeutics

8.81
+0.44005.26%
Post-market: 8.880.0700+0.79%19:52 EDT
Volume:2.91M
Turnover:25.85M
Market Cap:512.20M
PE:-3.57
High:9.24
Open:9.11
Low:8.71
Close:8.37
52wk High:40.37
52wk Low:2.96
Shares:58.14M
Float Shares:45.54M
Volume Ratio:1.12
T/O Rate:6.39%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4659
EPS(LYR):-2.2601
ROE:-73.70%
ROA:-33.63%
PB:2.08
PE(LYR):-3.90

Loading ...

Capricor Therapeutics Shares Rise After Upgrade From B. Riley

MT Newswires Live
·
8 hours ago

B. Riley Upgrades Capricor Therapeutics to Buy From Neutral, Raises Price Target to $21 From $5

MT Newswires Live
·
Yesterday

Capricor Therapeutics upgraded to Buy from Neutral at B. Riley

TIPRANKS
·
Yesterday

U.S. Research Roundup-ACV Auctions, Crown Castle, Lennox International

Reuters
·
Yesterday

Capricor Therapeutics Shares Rise After Piper Sandler Upgrade

MT Newswires Live
·
Sep 02

Capricor Therapeutics Price Target Raised to $25.00/Share from $2.00 by Piper Sandler

Dow Jones
·
Sep 02

U.S. Stocks on the MOVE-GoPro, TXNM Energy, Emergent BioSolutions

Reuters
·
Sep 01

U.S. Stocks on the MOVE-Robinhood Markets, Park Hotels & Resorts, Capricor Therapeutics

Reuters
·
Sep 01

Capricor Therapeutics upgraded to Overweight from Neutral at Piper Sandler

TIPRANKS
·
Sep 01

Analysts Offer Insights on Healthcare Companies: Capricor Therapeutics (CAPR) and Helus Pharma (HELP)

TIPRANKS
·
Sep 01

U.S. Research Roundup-Autodesk, Hubspot, Oracle

Reuters
·
Sep 01

Capricor Therapeutics call volume above normal and directionally bullish

TIPRANKS
·
Aug 26

U.S. Stocks on the MOVE-Azenta, Qiagen NV, Capricor Therapeutics

Reuters
·
Aug 24

Capricor Therapeutics Shares Rise as FDA Extends Deramiocel Review

Dow Jones
·
Aug 24

Wainwright says Capricor’s regulatory risk still high after FDA PDUFA extension

TIPRANKS
·
Aug 24

Capricor's Duchenne Drug Gets Three-Month FDA Extension After New Data Submission

Reuters
·
Aug 24

US FDA Extends Review of Capricor's Muscle Disorder Therapy by Three Months

Reuters
·
Aug 24

Capricor PDUFA Date for Deramiocel DMD Therapy Shifts to Nov. 22, 2026 After FDA Review Extension

Reuters
·
Aug 24

Capricor Therapeutics Announces Extension of Pdufa Target Action Date as FDA Continues Review of Deramiocel Bla

THOMSON REUTERS
·
Aug 24

Kaos Capital urges Capricor shareholders to support immediate board meeting

TIPRANKS
·
Aug 21